Tilray Medical wins Portugal approval. Tilray Brands stock is valued at USD 314.2 million
Published on 10/25/2026 at 14:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPortugal approval and operating scale
- Tilray Medical received Portugal testing approval on October 13, 2026.
- First-quarter revenue reached USD 257.15 million for the period ended August 31, 2026.
- Tilray Brands stock last stood at EUR 2.54 at Tradegate on October 23, 2026 at 9:40 p.m. CEST.
- The average analyst target was USD 5.90 on October 22, 2026.
Tilray Brands (ISIN US88688T2096) had a market capitalization of USD 314.2 million as of October 23, 2026. Tilray Medical received Portuguese approval for in-house quality testing on October 13, adding a concrete operating milestone to the company's latest growth figures.
According to Tilray, the INFARMED authorization covers microbiological and chemical and physical testing at the Cantanhede facility. The company said the approval should shorten testing timelines and support medical cannabis supply in regulated markets.
What does the quarter mean for margins?
Tilray reported first-quarter fiscal 2027 net revenue of USD 257.15 million for the three months ended August 31, 2026, up 23.00 percent from USD 209.50 million a year earlier. Tilray also reported gross profit of USD 77.51 million, up 35.00 percent, while gross margin increased to 30.00 percent from 27.00 percent.
The mix was uneven. Beverage revenue rose to USD 101.50 million from USD 55.74 million, while cannabis revenue fell to USD 56.11 million from USD 64.51 million in the same period. Net loss reached USD 40.03 million, compared with net income of USD 1.51 million a year earlier.
Three dated milestones and next dates
On October 8, 2026, Tilray reported USD 257.15 million in first-quarter revenue; on October 13, 2026, Tilray Medical received Portugal testing approval; on October 15, 2026, SweetWater launched a promotion with prizes valued at USD 1,200 each, according to Tilray.
The next scheduled corporate date is the annual shareholder meeting on November 18, 2026, at 11:00 a.m. EST, according to Tilray. The latest reported quarter also reaffirmed fiscal 2027 adjusted EBITDA guidance of USD 68 million to USD 75 million.
Stock context and valuation
Analyst expectations remain above the German euro quotation. MarketBeat reported an average Hold rating from eight brokerages and an average 12-month target of USD 5.90 on October 22, 2026, while Canaccord Genuity cut its target from USD 4.50 to USD 4.00 on October 9, 2026, according to MarketBeat. The contrast is clear: revenue growth is strongest in beverages, while cannabis revenue and overall profitability remain under pressure.
Last available euro quotation
The last available euro quotation stood at EUR 2.54 at Tradegate on October 23, 2026 at 9:40 p.m. CEST. Tilray Brands trades primarily on Nasdaq under the ticker TLRY, while its 52-week range was USD 2.80 to USD 15.70 as of October 23, 2026.
The further course of trading is shown by the continuously updated real-time quote of Tilray Brands stock.
Tilray Brands stock facts
- Company: Tilray Brands, Inc.
- ISIN: US88688T2096
- Ticker: TLRY
- Primary exchange: Nasdaq
- Market capitalization: USD 314.2 million (as of October 23, 2026)
- 52-week range: USD 2.80-15.70 (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report S&P 500.
